Medplus Health Services has witnessed a significant reduction in pledged equity shares following a release transaction by Catalyst Trusteeship Limited. The debenture trustee released 41,71,970 pledged equity shares on December 24, 2025, marking a notable change in the company's encumbrance structure.

Share Release Details

Catalyst Trusteeship Limited, acting as Debenture Trustee on behalf of debenture holders, executed the release of pledged shares under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011. The transaction involved the release of shares that were previously held as encumbrance.

Impact on Shareholding Pattern

The share release has resulted in a substantial reduction in the encumbered shareholding percentage. Prior to this transaction, Catalyst Trusteeship Limited held 1,07,98,429 shares under encumbrance, representing 9.01% of the total share capital.

Company Capital Structure

Medplus Health Services' equity structure remains stable despite the pledge release transaction. The company maintains its total equity share capital without any changes to the underlying share count or face value.

Current Capital Structure:

• Total Equity Share Capital: ₹23.96 crores
• Number of Equity Shares: 11,98,22,581
• Face Value per Share: ₹2.00
• Total Diluted Share Capital: ₹24.05 crores (12,02,53,747 shares)

Regulatory Compliance

The disclosure was made pursuant to Regulation 29(2) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011. Catalyst Trusteeship Limited submitted the required documentation to both NSE and BSE, ensuring full regulatory compliance for the share release transaction.

The transaction represents a standard debenture-related pledge release, with Catalyst Trusteeship Limited continuing to hold a reduced but significant encumbrance position in Medplus Health Services.

Medplus Health Services Limited has informed stock exchanges about regulatory action taken against its subsidiary operations in Karnataka. The company disclosed that Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, received suspension orders for drug licenses at three retail locations.

Regulatory Action Details

The suspension orders were issued by the Assistant Director, Drugs Control Administration from two different circles in Karnataka. The company received the orders on December 23, affecting stores in strategic locations across the state.

Store Locations and Financial Impact

The suspensions affect three stores across different regions in Karnataka, with varying financial implications for each location.

Compliance and Disclosure

The disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has fulfilled its regulatory obligations by informing both BSE Limited and National Stock Exchange of India Limited about the developments.

The violations were reported under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, indicating regulatory compliance issues at the subsidiary level. The company has made the complete details available on its website and the respective stock exchange platforms for stakeholder access.

Corporate Structure Impact

The regulatory action affects Optival Health Solutions Private Limited, which operates as a subsidiary under the Medplus Health Services umbrella. The financial impact of the suspensions is estimated at ₹3.24 across all affected stores, highlighting compliance challenges in the company's retail pharmacy operations in Karnataka.